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The role of platelets extends beyond hemostasis. The pivotal role of platelets in inflammation has shed new light
on the natural history of conditions associated with acute or chronic inflammation. Beyond the preservation of
vascular integrity, platelets are essential to tissue homeostasis and platelet-derived products are already used in the
clinics. Unanticipated was the role of platelets in the adaptative immune response, allowing a renewed conceptual
approach of auto-immune diseases. Platelets are also important players in cancer growth and dissemination.
Platelets fulfill most of their functions through the expression of still incompletely characterized membrane-bound
or soluble mediators. Among them, CD154 holds a peculiar position, as platelets represent a major source of CD154
and as CD154 contributes to most of these new platelet attributes. Here, we provide an overview of some of the
new frontiers that the study of platelet CD154 is opening, in inflammation, tissue homeostasis, immune response,
hematopoiesis and cancer.
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Platelets are cytoplasmic fragments released in the blood-
stream during the fragmentation of polyploid megaka-
ryocytes (MK), a phenomenon critically dependent on
thrombopoietin [1-3]. The mammalian platelet is thought
to result from a phylogenic trend to ensure hemostasis
under high vascular shear forces; indeed, it can specifically
form arterial thrombi sustaining high shear stress [4]. It is
thought that the platelet coopted attributes of a nucle-
ated cell ancestor endowed with a multifunctional role
in coagulation, inflammation and defense against infec-
tions [5,6]. Platelets have a short lifespan, of around
7 days; mechanisms responsible for their clearance are
ill-understood; lectin-carbohydrate recognition of aged
and damaged platelets by splenic and liver macrophages
and hepatocytes is emphasized [7]. The best-defined func-
tion of platelets is hemostasis. Disruption of the endothe-
lial cell (EC) lining leads to platelet activation, platelet
adherence and aggregation which temporarily plug the
damaged vessel. In this process, platelets also drive and
confine coagulation at sites of tissue damage. Indeed, defi-
ciencies in platelet production or function are associated
to bleeding disorders, while increases in platelet number* Correspondence: jean.ripoche@u-bordeaux2.fr
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unless otherwise stated.or gain of function are associated to thrombosis. The
role of platelets in health and disease extends beyond
hemostasis; non-hemostatic platelet functions include
inflammation, innate and adaptative immune responses
and tissue homeostasis (Figure 1). Decisive advances in
understanding platelet function have been made through
the characterization of platelet receptors and their ligands
and platelet-derived mediators [8]. Among platelet me-
diators, CD154, the ligand of CD40, has attracted spe-
cific attention as it orchestrates many of these new
platelet attributes.CD154
CD154, the CD40 ligand, a member of the Tumor Necro-
sis Factor (TNF) family, is central to the immune response
[9,10]. CD154 was discovered as mediating humoral im-
munity and was originally considered to be restricted to
activated helper T cells. The CD154/CD40 interaction
drives B cell proliferation, antibody production and iso-
type switching and is involved in thymic selection. This
interaction is required for B memory cell generation and
germinal center formation. Accordingly, CD154 deficiency
is associated with an impairment of the humoral im-
mune response to T-cell dependent antigens, including
defective immunoglobulin class switching; patients with
the X-linked hyper-IgM syndrome caused by mutationsl. This is an Open Access article distributed under the terms of the Creative
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Figure 1 Platelets have a pleiotropic range of biological roles that extend beyond hemostasis. The breaching of tissue homeostasis leads
to platelet activation, a common event in various causes of tissue injury, traumatic, infectious, ischemic, autoimmune… Platelet activation, apart
from its essential role in bleeding arrest, is the source of a flow of information that fuels the inflammatory reaction. Platelets represent host defense
machines against infection, via the clearing of pathogens and the expression of membrane-bound and soluble signals that regulate the innate and
adaptative arms of the immune response. Pathways activated in inflammation, coagulation, vascular/tissue repair and host defense are connected via
soluble and cell-mediated signals, providing a coherent biological response aiming at arresting bleeding, curing infection and reestablishing tissue
homeostasis. CD154 interfaces with many of these pathways (see Figures 2 and 3); activated platelets express a membrane-bound form of CD154 and
release a soluble form (sCD154). Platelet derived microparticles (PMPs) recapitulate several of activated platelet functions (see text for details). Only
some relevant molecules have been depicted. Small circles symbolize secreted molecules, large circles membrane-associated molecules. Abbreviations:
CAMs, cell adhesion molecules; Fg, fibrinogen; Fn, fibronectin; ECM, extracellular matrix; NET ind., neutrophil extracellular traps induction; PAF, platelet
activating factor; ROS, reactive oxygen species; Vn, vitronectin; vWF, von Willebrand factor.
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and IgA, but normal or increased serum IgM, and are
susceptible to opportunistic infections. Mice with a dis-
rupted Cd154 gene fail to undergo isotype switching to
T-cell dependent antigens while normally responding to
T-cell independent antigens. In line with its regulatory
role on the adaptative immune response, the CD40/
CD154 interaction contributes to autoimmune disorders
in a number of animal models [11-15]. Manipulation of
the CD154/CD40 interaction has been used in efforts to
develop novel strategies in autoimmune diseases, results
in animal models being encouraging [13]. Clinical trials
have been launched with humanized anti-CD154 mono-
clonal antibodies. Clinical interest of this strategy re-
mains mixed, and is strongly limited by thrombotic
complications [12-14].
Apart from B cells, CD40 is expressed by various cells,
including dendritic cells (DC), monocytes, T lympho-
cytes, EC, a variety of epithelial cells, smooth muscle
cells, fibroblasts; its expression is low in basal conditions
and is stimulated by inflammatory mediators [16-19].
CD40 expression is increased by CD154, however it is notknown whether this induction is direct or indirect [20,21].
CD40 is not the sole receptor for CD154; alternative
receptors have been described, such as integrins α5β1,
αIIbβ3 and αMβ2; CD154 binding depends on their
activation states [22-25]. These additional receptors are of
significance in the pathophysiology of atherogenesis and
are important to consider when comparing CD40- and
CD154-deficient mouse phenotypes.
CD154 is a transmembrane protein and a proteolytic
soluble form, sCD154, which keeps the CD40-binding do-
main, is released by a partially understood mechanism.
The release of sCD154 was first documented in activated
T-lymphocytes [26]. CD154 has a trimeric configuration,
required for functional activity [27-30]. A complex signal-
ing cascade is triggered by CD40 ligation, involving TNF
receptor-associated factors (TRAF) as proximal transdu-
cing signal initiators [10,20]. Several signaling pathways,
including nuclear factor-κB (NF-κB), c-Jun N-terminal
kinase (JNK) and p38 mitogen-activated protein kinase
pathways, are activated by CD40 ligation; however, there
is a differential outcome depending upon which TRAF
member binds preferentially, and which cell/conditions
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vascular inflammation and metabolic complications as-
sociated with obesity [32,33].
CD154 expression is also observed in natural killer
cells, DC, cells of the monocyte/macrophage lineage,
endothelial, smooth muscle and epithelial cells [20]. Basal
CD154 expression is very low, or undetectable, as in EC
and epithelial cells for example [34], and is increased by a
variety of stimuli, most notably inflammatory cytokines
[20]. This suggests that CD154 expression may mostly
have relevance when induced, as in inflammation. CD154
is also expressed by blood platelets, being cryptic in un-
stimulated platelets and rapidly exposed at the platelet
surface following platelet activation [35].
CD154 expression by platelets
The distribution of CD154 in platelets is partly under-
stood. CD154 was found in α-granules, as shown by
immunoelectron microscopy or quantitative immuno-
fluorescence approaches [36,37]. Accordingly, patients
presenting a Gray-platelet syndrome, are characterized
by platelets that lack α-granules, and do not release
CD154 upon activation [37]. CD154 is highly coclustered
with insulin growth factor in α-granules, the signification
of which is unknown [36]. One question is whether
CD154 is also cytosolic, as found in resting platelets [38].
Pre-mRNAs and mature mRNAs are present in platelets
and a functional spliceosome and translational apparatus
allow platelets to process them, in response to platelet-
activating signals [39,40]. Detecting CD154 mRNA by RT-
PCR in platelets is challenging because of purity issues.
However, CD154 mRNA was evidenced in mouse plate-
lets, introducing other potential regulatory layers of
CD154 expression by platelets [34].
When activated, platelets express a membrane form and
release a soluble form of CD154
Platelets are activated by immobilized or soluble agonists.
The activation-driven secretion of granule content is a pri-
mary phenomenon [41-46]. Platelets also synthetize media-
tors, including interleukin-1β, tissue factor (TF), fibrinogen,
thrombospondin, von Willebrand Factor, αIIbβ3, through a
translational-dependent pathway triggered by platelet acti-
vation [47,48].
Soluble CD154 is released by an activation-driven pro-
teolytic mechanism. Agonists, including thrombin, throm-
bin receptor-agonist peptide, ADP or collagen, stimulate
CD154 expression at the platelet membrane and the re-
lease of sCD154; long-term platelet activation leads to
complete conversion of CD154 to sCD154 [38,49-53]. A
matrix metalloproteinase (MMP)-dependent proteolytic
event is involved. The involvement of MMPs, MMP-2
and/or MMP-9, [51,54-57], differs from the release of
sCD154 by activated T-cells, which involves ADAM10and 17 [58]. A role for αIIb/β3 has been put forward, as
αIIb/β3 antagonists inhibit sCD154 release and as
Glanzmann platelets show reduced sCD154 release rate
[53,54,59]. An interaction between αIIb/β3 and MMP-2
is involved [57]. The roles of NADPH activation and
reactive oxygen species (ROS) generation as well as
CD154 binding to platelet CD40 have been underlined
[50,60]. The particularity of sCD154 release may explain
its specific response to agonists and secretion kinetics
[38,53]; however, how sCD154 is released remains be
fully understood, as shown for example by the effects of in-
hibitors added after platelet activation, suggesting complex,
intra-platelet mechanisms [53]. A debate remains about
the parallel biological activities of platelet-derived soluble
and membrane-associated CD154; recombinant soluble
forms, particularly trimeric forms, are active [50,61-63]. Fi-
nally, sCD154 activates platelets by itself, suggesting feed-
back amplification of its secretion [64,65].
The megakaryocytic origin of platelet CD154
The assembly and loading of granules mainly occur in MK;
granules are distributed in proplatelets via a microtubule-
dependent mechanism [2,66,67]. The main origin of plate-
let CD154 is likely to be the MK that express CD154
mRNA, as shown in MK derived by differentiation of
human and mouse hematopoietic progenitor cells and
in MK of immune thrombocytopenic purpura (ITP) pa-
tients [68,69]. CD154 mRNA expression is increased
upon MK differentiation [69]. CD154 protein is also found
in MK cell lines and in MK from ITP patients [38,68,69].
As for T cells, the calcium-dependent activation of nuclear
factor of activated T cells-c2 and the early growth re-
sponse transcription factor EGR-1 contribute to CD154
gene activation in MK [69,70].
Translation from endogenous mRNAs contributes to
platelet content. Its significance in quiescent platelets is
unclear. However, pre-mRNA processing and mRNA
translation are driven by platelet activation [40,48,71]. The
contribution of such mechanism in CD154 expression
during platelet lifespan is unknown.
Platelets also carry mediators present in plasma and pos-
sibly concentrated and/or modified within platelets [72,73].
Fibrinogen, albumin, immunoglobulins, amino acids, in-
flammatory and angiogenic mediators including vascular
endothelial growth factor (VEGF), histamine or serotonin,
are among them. Soluble CD154 is not detected in plate-
lets, making unlikely its uptake from plasma.
Platelets are a significant reservoir of CD154 in the organism
Platelets carry approximately 5 ng of CD154/mL of blood
[52]. Correlation studies suggest a link between platelet
count and plasma or serum sCD154 [37,52,74-78]. Such a
correlation is also found in experimental ITP [78]. In ITP,
albeit platelet CD154 is elevated [68], plasma sCD154 is
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platelet count and circulating sCD154. However, there are
contrasting studies, and a correlation between the platelet
count and sCD154 is not always found [79,80].
Importantly, platelet activation is associated to elevated
sCD154 and, indeed, platelet activation markers correlate
with sCD154 in blood [81-83]. For this reason, serum
seems inappropriate to evaluate circulating sCD154; in fact,
sCD154 levels are higher in serum than in plasma, clotting
resulting in increased sCD154 generation [52,79,80,84-88].
Hence the importance of a preanalytical standardization of
blood samples processing, conditions such as temperature,
length of storage, centrifugation, interfering with meas-
urement [84,89]. Further, plasma/serum sCD154 may
correspond to a pool of free soluble and microparticle-
bound CD154 [84] and ELISA may not discriminate
between sCD154 and platelet microparticles (PMP)-
associated CD154 [90]. Circulating sCD154 is linked to
platelet activation state; in patients with recent throm-
botic events, plasma sCD154 correlates with platelet
count, but this correlation is not found in patients with
non-thrombotic, non-inflammatory conditions [84]. Fi-
nally, in patients with cardiovascular conditions, com-
monly used drugs such as statins, interfere with sCD154
releasing, a point that has also to be considered [91-93].
The baseline presence of sCD154 in the plasma of
healthy subjects may be secondary to basal platelet acti-
vation, as in high shear stress flow areas [94]. PMP are
released upon platelet activation [95]. A functional
CD154 is expressed by PMP [63,96]. The importance of
the contribution of PMP-bound CD154, in comparison
with the “true” soluble CD154, to plasma sCD154 has
been emphasized [90]. Questions also remain on the fate
and half-life of sCD154 in blood and how the CD154
information can be delivered at distance from platelet
activation sites.
Platelet CD154: a critical mediator of the inflammatory
reaction
Platelets orchestrate a subtle balance between tissue injury
and repair; they are a key source of material for reestab-
lishing tissue homeostasis but they also contribute to tis-
sue injury. CD154 mediates several platelet functions in
tissue homeostasis (Figure 2).
Platelet CD154 and inflammation Regardless of its
cause, the inflammatory milieu is rich in platelet-activating
material, including chemokines [98]. The dialog between
EC and platelets in inflammation has been widely studied
as EC are primary platelet partners. Upon CD40 ligation,
EC switch to an activated phenotype, expressing molecules
that contribute to an inflammatory and thrombotic
scenario, including cytokines/chemokines, adhesion mole-
cules, and tissue factor [16,20,99]. Platelets/EC reciprocalactivation is critical in atherosclerosis and cardiovascular
conditions [100-103]. The pathogenic role of platelet
CD154 is a major theme in atherosclerosis and cardio-
vascular diseases [25,62,74,100-109].
The role of platelet CD154 in inflammation extends
beyond the dialog with EC, as activated platelets interact
with various CD40 expressing-cells. Platelets are brought
to inflammatory sites via vascular injury/permeability, at-
tachment to activated leukocytes, and also chemotactic
recruitment [110]. CD40 ligation on inflammatory cells
at sites of tissue injury is a potent stimulus for the expres-
sion of a variety of proinflammatory mediators including
cytokines, chemokines, eicosanoids, products of the
proteolytic cascades, ROS generation, and of adhesion
molecules [49,111], making platelet CD154 a versatile
fuel for inflammation. The platelet contribution in many
inflammation-associated disorders, including rheumatic,
lung, gastrointestinal, neuro-inflammatory and metabolic
diseases is actively studied [112-120] and the specific
pathogenic role played by platelet CD154 in these disor-
ders is a recently opened frontier. Soluble CD154 levels
were found to correlate with disease activity as in systemic
lupus erythematosus [121]; whether sCD154 could repre-
sent a potential useful marker in inflammation-associated
disorders is an interesting question. PMP also contrib-
ute to inflammatory disorders [122-128]; the specific
role of PMP-associated CD154 remains however to be
fully understood.
Platelet CD154 and tissue repair The effectors of in-
flammation are orchestrated to cure infection and re-
store tissue integrity [129-131]. At various steps of tissue
repair, platelets are a source of relevant material, including
growth factors, pro- and anti-apoptotic mediators, matrix
and matrix remodeling proteins [132-135] (Figure 1). Plate-
lets contribute to maintain resting and injured endothe-
lium integrity [136]. On injured endothelium, platelets
provide EC growth-promoting and anti-apoptotic media-
tors, attractants for progenitor cells endowed with vascular
healing properties [135]. They contribute to restoring the
vascular network, by secreting regulators of angiogenesis
[137-139]. Beyond endothelium, a remarkable role for
platelets in organ regeneration has been substantiated.
Platelets contribute to liver regeneration, serotonin being
essential [140-142]. It is tempting to speculate that platelets
will be found to have a broader role in organ regeneration
by providing key mitogenic signals in various organs, such
as for example fibroblast growth factor or platelet-derived
growth factor that contribute to muscle or brain repair
[143,144]. This is also in line with the known ability of
platelet lysates to sustain the growth of primary cell cul-
tures. PMP also contribute to vascular integrity [145-148]
and promote tissue repair [128,149]. Platelet products have





Figure 2 CD154 is a universal contributor to platelet functions. Activated platelets display CD154 at their membrane and release a soluble
form (sCD154). Platelet CD154, directly or indirectly, is a molecular driver of inflammation, coagulation, tissue remodeling, and host defense,
processes that intersect at multiple levels. Endothelium is a primary target. Platelet CD154 induces tissue factor (TF) expression and activity,
thereby contributing to thrombin generation and upregulates urokinase plasminogen activator receptor which is at the interface between
fibrinolysis/inflammation/tissue remodeling. MMP-9 and MT1-MMP induction contribute to regulate endothelium proteolytic activity [97]. Platelet
CD154 also induces pro-inflammatory and chemotactic (dotted semicircles) molecule expression, and adhesion molecule expression (CD62e,
CD54, CD106,…), leading to leukocyte recruitment and activation. Once activated, target cells recruit and activate other cells through multiple
inputs; several amplification loops are thus generated including platelet activation by sCD154 itself (blue arrow). Platelet CD154 also activates
cellular effectors of the innate and adaptative immune responses, polymorphonuclear cells (PMN), monocytes (MNC), macrophages (MΦ),
dendritic cells (DC); how platelet CD154 contributes to host defense is schematized in Figure 3. CD154-expressing platelet microparticles (PMPs)
share most of these functions. Depicted molecules do not comprehensively represent the range of platelet-derived mediators that are controlled
by platelet CD154, and other interfaces, such as with endothelin-1, continue to be identified. Magenta arrows depict interaction with CD40.
Dotted line for thrombomodulin (ThMod) represents inhibition; full line for others represents stimulation. Dotted semicircles symbolize chemotaxis.
Abbreviations: Ly, lymphocytes; MMP, matrix metalloproteinases.
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EC. CD154 promotes EC survival, proliferation and
migration, capillary-like tube formation in vitro and
angiogenesis in vivo. Mechanisms include activation of
the phosphatidylinositol-3 kinase/Akt pathway, induc-
tion of angiogenic mediators and matrix remodeling
protein production [155-157]. CD40 signaling contrib-
utes to neointima repair, TRAF6 signaling intermediate
being critical [32,158,159]. However, platelet CD154 was
shown to inhibit the VEGF-induced EC migration via in-
creased ROS generation, and sCD154 to inhibit VEGF-
induced angiogenesis [160]. Soluble CD154 also promotes
oxidative stress in endothelial outgrowth cells (EOC), redu-
cing their viability and proliferation [161], while promoting
endothelial repair via increased production of MMP-9 by
EOC [162]. These findings may be context-dependent; they
emphasize the importance of platelet CD154 in vascular
homeostasis and the complexity of its biological interfaces.
Other tissues for which platelet CD154 is likely to showimportance for repair are skin and bone. CD40 ligation
stimulates keratinocyte differentiation, suggesting contri-
bution to skin wound repair [163]. Regulation of osteo-
clastogenesis by CD154 is suggested by the reduced bone
mineral density together with elevated urine markers of
osteoclast activity in patients with the X-linked hyper-IgM
syndrome, and the reduced bone mineral density in
CD154 deficient mice [164,165]. CD40 is expressed by
osteoblastic cells and CD154 is anti-apoptotic in these cells
[166]. Therefore, much remains to be found about the role
of platelet CD154 in tissue repair. As CD40 is largely dis-
tributed, platelet CD154 could be conjectured to be gener-
ally involved, to one degree or another, in tissue repair.
Platelet CD154 as a mediator of tissue injury The
model of platelets promoting tissue repair is to be com-
pared to their deleterious role in acute and chronic tis-
sue injury. Difficult points are raised by this friend or foe
facet, implicating balanced therapeutic approaches [119].
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ous role, and the importance to control platelet activation
in this context. In I/R, platelet activation in the microcir-
culation vascular bed leads to tissue injury, as shown in
lung, liver or kidney. Platelet depletion or antiplatelet
treatments are protective in several experimental I/R
models [167-169]; CD154 is contributing: mice deficient
in CD154 are protected from I/R-mediated injury in brain,
lung, liver or intestine; in lung I/R-mediated injury platelet
CD154 is specifically contributing [170-172].
Platelet CD154 and the immune response: unanticipated
new frontiers
Platelets participate to the control of infection via direct
and indirect mechanisms [6,173-178]. The significance
of platelet Toll-like receptors (TLR) has been empha-
sized; TLR ligation activates platelet secretion of media-
tors regulating the immune response, including sCD154
[6,179-184]. Platelets also regulate several steps of the
adaptative immune response [6,182-194]. Moreover, plate-
lets can present antigen [195]; they express MHC class IFigure 3 Platelet CD154 contributes to the host defense against infec
with pathogens, pathogen-derived molecules such as lipopolysaccharide (L
to CD154 display at the platelet membrane and the release of soluble CD1
including soluble and cellular effectors of the inflammatory network. Platele
contribution to the chemotactic recruitment (dotted semicircles symbolize
induction of adhesion molecules on EC (CD62e, CD54, CD106) and activati
CD40 triggering is a major inducer of pathogen-killing mechanisms by pha
generated upon CD40 ligation; this schematic representation does not rep
CD154. Platelet CD154 influences the adaptative immune response, throug
presenting cells (see text for details). Magenta arrows depict interaction wi
patterns; PRR, pathogen recognition receptors; TLR, Toll-like receptors.molecules and T cell costimulatory molecules, including
CD86 and CD40 and harbor a functional proteasome
[196-199]. Among platelet mediators, CD154 proved to be
critical in linking platelet and immunity (Figure 3).
Although much remains to be understood, particularly
with reference to the innate immune response, the specific
role of platelet CD154 in immunity is strengthening.
Several pathogen-clearing mechanisms are stimulated by
CD154, including platelet aggregation [173], phagocytosis
and production of defense proteins, such as complement
proteins and interferon-α, by cells of the innate immune
system [6,20,201]. CD40 contributes to the regulation of
innate immune response, including induction of TLR
expression, cooperation in TLR-mediated B cell activa-
tion, engagement in the crosstalk between intracellular
MHC class II molecules and TLR signaling pathway
[202-204]. The specific role of platelet CD154 in these
mechanisms remains to be precised. However, it is now
appreciated that platelet CD154 controls many facets of
the interface between innate and adaptive immune re-
sponses [173,187,191,205]. Platelet CD154 induces DCtions. Infection triggers inflammation and coagulation. The interaction
PS), inflammation and coagulation concur to activate platelets, leading
54 (sCD154). Multiple inputs amplify the platelet activation scenario,
t CD154 targets several immune response effectors, including
chemotaxis) of leukocytes to sites of infection, e.g. through the
on/upregulation of integrins such as αMβ2 on neutrophils [158,200].
gocytic cells. These responses are amplified by inflammatory mediators
resent all interfaces that are directly or indirectly regulated by platelet
h several mechanisms, including the activation/maturation of antigen
th CD40. Abbreviations: PAMPs, pathogen-associated molecular
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isotype switching, contributes to germinal center formation,
and enhances CD8+ T cell responses [188,206-213]. Platelet
CD154 helps mounting a protective cytotoxic T cell im-
mune response to viral or bacterial challenge [206,214].
Platelet CD154 may promote the immune response in the
context of low antigen challenge by lowering the antigen
threshold, and improve B cell response in regulatory
T-cell limiting settings [210,215]. Further, sCD154 per se
induces cardiac allograft rejection [212]. Many questions
remain. How platelet CD154 enters the draining lymph
nodes to regulate the adaptive immune response machin-
ery is not known; PMP may convey this information, as
CD154 associated to PMP is functional: it enhances DC
activation, germinal center formation, B cell proliferation
and IgG production [63,216]. Several questions are also
raised with reference to platelet CD154 in autoimmunity;
this “dark side” [14,217] feature of platelet CD154 is a
recently opened frontier. Platelet CD154 is competent
to increase production of antiplatelet antibodies in im-
mune thrombocytopenic purpura [68] and, in systemic
lupus erythematosus, platelet CD154 activates antigen
presenting cells contributing to enhanced interferon-α
production [218].
Platelet CD154: a new hematopoietic regulator?
Hematopoiesis can be adapted in response to inflamma-
tion/infection by signals generated at bone marrow distal
sites [219-224]. Platelets are activated at sites of inflamma-
tion/infection and are a major source of circulating
sCD154. Could platelets deliver a CD154 signal, through
sCD154, platelet- or PMP-associated CD154 that regulates
hematopoiesis? Platelet mediators enhance hematopoietic
stem cell proliferation and platelet-derived signals may
contribute to CD34+ cell mobilization [225,226]. Sev-
eral studies have demonstrated CD154 involvement in
hematopoiesis. CD154 regulation of early B cell lympho-
poiesis is suggested by the sCD154-induced increased
number of B cell progenitors (BCP) in mice after bone
marrow transplantation (BMT) [227]. CD40 is expressed
on BCP, and a positive effect of CD40 ligation on BCP
proliferation can be observed on pre- and immature B
cells in human and pro-B cells in the mouse [228,229]. In
the mouse, there is clear experimental evidence for a posi-
tive role of CD154 in B cell hematopoiesis and, particu-
larly in stress conditions, as after BMT [229]. However,
normal numbers of circulating B cells in patients with X-
linked hyper-IgM syndrome would rule out an absolute
requirement for the CD154/CD40 signaling in early B cell
development. CD154 may therefore mostly play a signifi-
cant role in emergency B cell hematopoiesis [229]. More
is known about CD154 regulation of the lymphoid system
maturation, which has been fully reviewed [230]. A role
for platelet CD154 on myelopoiesis is suggested by thesCD154-mediated increased granulocyte and platelet re-
covery after BMT in the mouse and by the neutropenia
and thrombocytopenia observed in patients with X-linked
hyper-IgM syndrome [227]. In vitro, sCD154 promotes the
differentiation of CD34+ cells towards the granulocytic/
monocytic and megakaryocytic lineages in CD34+/stromal
cell cocultures. The mode of action of sCD154 appears
to be essentially indirect, through the induction of
hematopoietic cytokines by bone marrow stromal cells
[231,232]. Platelet CD154 may therefore play a role in
regulating emergency hematopoiesis. However, many
questions remain unsolved, particularly which and how
platelet CD154 signals could be delivered and interact
with bone marrow stem/progenitor cells.
Platelet CD154 and cancer: a rapidly expanding frontier
There is strong evidence for the involvement of platelets
in cancer progression; mechanisms are multiple [233-240].
Platelets are activated in the tumor environment and bind
tumor cells. Mediators released upon platelet activation
are key to tumor angiogenesis [241,242] and are likely to
contribute to the tumor-supporting inflammatory environ-
ment [243,244]. Platelets play a positive role in metastasis
[234,238,245-249]. However, this may not be true for all
organs [250]. In hematogenous dissemination, platelet/
cancer cell microthrombi provide protection, including
shielding from shear flow, or immune evasion; during
the arrest and extravasation phases, platelet mediators
facilitate tumor cell arrest on EC, extravasation, survival
and growth after seeding [251]. Platelet MPs are also
contributing [124,252,253].
Many tumor cells express CD40. The outcomes of
CD40 ligation on tumor cells are ambivalent depending
on the models studied. In one hand, CD40 ligation pro-
motes anti-tumor immune surveillance through a variety
of mechanisms including antigen-presenting cell activation,
restoration of malignant cell immune recognition, activa-
tion of tumoricidal-infiltrating macrophages, immunosti-
mulatory cytokine production. CD40 ligation also induces
tumor growth arrest and sensitization to apoptotic signals.
On the other hand, CD40 ligation has positive conse-
quences on tumor growth, survival and resistance to
chemotherapy and metastatic potential. The interpret-
ation of CD154 effects on cancer cells is made complex,
first by the existence of several receptors for CD154, po-
tentially explaining variable outcomes of CD154 treat-
ment of tumor cells, and second, by the difficulty in
assessing direct versus indirect effects. The contribution
of the CD40 signaling in cancer, and prospects offered
by targeting the CD40 signaling for cancer treatment have
recently been underlined and reviewed [254-258]. How-
ever, the specific role played by platelet CD154 remains a
new important frontier. If platelet activation is likely to re-
sult in expression of CD154 and generation of sCD154 in
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as there are extra platelet sources of CD154.
Conclusion
There have been recent and rapid advances in our current
knowledge of the non-hemostatic functions of platelets,
placing them in the middle of the spectrum of mecha-
nisms that maintain homeostasis, and highlighting their
role in a variety of inflammatory and immune disorders.
However, platelets store and release such a wide diversity
of biologically active mediators that major gaps remain in
our understanding of which and how these mediators
collectively fulfill these functions. Platelet CD154 has
attracted considerable attention as it recapitulates several
of non-hemostatic platelet attributes. Considering the
large number of different cells expressing CD40, the
complex signaling cascade and the wide range of effec-
tors activated by the CD154/CD40 interaction, it can be
anticipated that future investigations will further extend
the contribution of platelet CD154 in health and dis-
ease. For example, recent publications on the CD154/
CD40 dyad have pointed to its role in obesity and hep-
atic steatosis [259-263], and it is tempting to speculate
that platelet CD154 contributes to metabolic homeosta-
sis. In the same direction, the number of physiological
or pathological conditions associated with platelet acti-
vation is enlarging. For example, platelet activation has
been found associated to aging, to emotional or environ-
mental stresses…; platelet CD154 might represent a sig-
nificant link between these conditions and accompanying
pathologies, such as cardiovascular events [264]. However,
platelet CD154 is always acting in a multicytokine context,
including inhibitors and activators released at the same
time by platelets; understanding how this complexity is
tuned and evidencing the specific role of platelet CD154
remains a difficult challenge.
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